- Precision BioSciences Inc DTIL and Tiziana Life Sciences plc TLSA have announced an exclusive license agreement for Tiziana's foralumab.
- The companies plan to explore the fully human anti-CD3 monoclonal antibody as an agent to induce tolerance of allogeneic CAR T cells.
- Under the terms of the agreement, Precision gains an exclusive license to use foralumab as a lymphodepletion agent in conjunction with its allogeneic CAR T therapeutics for the treatment of cancers.
- Precision will be responsible for the development, commercialization, and costs. Tiziana will receive an upfront payment, certain milestone payments, and royalties.
- Specific deal terms were not disclosed.
- Price Action: DTIL stock is +1.17% at $13.85, and TLSA stock is up 19.6% at $1.97 during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
